Now showing items 1-17 of 17

    • Abi1 loss drives prostate tumorigenesis through activation of EMT and non-canonical WNT signaling 

      Nath, Disharee; Li, Xiang; Mondragon, Claudia; Post, Dawn; Chen, Ming; White, Julie R; Hryniewicz-Jankowska, Anita; ... (19 authors) (Cell Communication and Signaling, 2019-12)
    • An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer. 

      Chen, Ming; Zhang, Jiangwen; Sampieri, Katia; Clohessy, John G; Mendez, Lourdes; Gonzalez-Billalabeitia, Enrique; Liu, Xue-Song; ... (23 authors) (Nature genetics, 2018-02)
      Lipids, either endogenously synthesized or exogenous, have been linked to human cancer. Here we found that PML is frequently co-deleted with PTEN in metastatic human prostate cancer (CaP). We demonstrated that conditional ...
    • Compound haploinsufficiency of Dok2 and Dusp4 promotes lung tumorigenesis. 

      Chen, Ming; Zhang, Jiangwen; Berger, Alice H; Diolombi, Moussa S; Ng, Christopher; Fung, Jacqueline; Bronson, Roderick T; ... (12 authors) (The Journal of clinical investigation, 2019-01)
      Recurrent broad-scale heterozygous deletions are frequently observed in human cancer. Here we tested the hypothesis that compound haploinsufficiency of neighboring genes at chromosome 8p promotes tumorigenesis. By targeting ...
    • Deregulated PP1α phosphatase activity towards MAPK activation is antagonized by a tumor suppressive failsafe mechanism. 

      Chen, Ming; Wan, Lixin; Zhang, Jiangwen; Zhang, Jinfang; Mendez, Lourdes; Clohessy, John G; Berry, Kelsey; ... (12 authors) (Nature communications, 2018-01-15)
      The mitogen-activated protein kinase (MAPK) pathway is frequently aberrantly activated in advanced cancers, including metastatic prostate cancer (CaP). However, activating mutations or gene rearrangements among MAPK signaling ...
    • DOK2 inhibits EGFR-mutated lung adenocarcinoma. 

      Berger, Alice H; Chen, Ming; Morotti, Alessandro; Janas, Justyna A; Niki, Masaru; Bronson, Roderick T; Taylor, Barry S; ... (12 authors) (PloS one, 2013-01)
      Somatic mutations in the EGFR proto-oncogene occur in ~15% of human lung adenocarcinomas and the importance of EGFR mutations for the initiation and maintenance of lung cancer is well established from mouse models and cancer ...
    • Endosome and INPP4B. 

      Chew, Chen Li; Chen, Ming; Pandolfi, Pier Paolo (Oncotarget, 2016-01)
    • In Vivo Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K-AKT Signaling at Endosomes. 

      Li Chew, Chen; Lunardi, Andrea; Gulluni, Federico; Ruan, Daniel T; Chen, Ming; Salmena, Leonardo; Nishino, Michiya; ... (16 authors) (Cancer discovery, 2015-07)
      The phosphatases PTEN and INPP4B have been proposed to act as tumor suppressors by antagonizing PI3K-AKT signaling and are frequently dysregulated in human cancer. Although PTEN has been extensively studied, little is known ...
    • Interplay between c-Src and the APC/C co-activator Cdh1 regulates mammary tumorigenesis 

      Han, Tao; Jiang, Shulong; Zheng, Hong; Yin, Qing; Xie, Mengyu; Little, Margaret R; Yin, Xiu; ... (12 authors) (Nature Communications, 2019-12)
    • Loss of LDAH associated with prostate cancer and hearing loss. 

      Currall, Benjamin B; Chen, Ming; Sallari, Richard C; Cotter, Maura; Wong, Kristen E; Robertson, Nahid G; Penney, Kathryn L; ... (29 authors) (Human molecular genetics, 2018-12)
      Great strides in gene discovery have been made using a multitude of methods to associate phenotypes with genetic variants, but there still remains a substantial gap between observed symptoms and identified genetic defects. ...
    • Pills of PTEN? In and out for tumor suppression. 

      Papa, Antonella; Chen, Ming; Pandolfi, Pier Paolo (Cell research, 2013-10)
      The tumor-suppressive activity of PTEN has always been attributed to its endogenous intracellular function. Recently two different groups have demonstrated that PTEN is secreted/exported into the extracellular environment ...
    • Preclinical and Coclinical Studies in Prostate Cancer. 

      Chen, Ming; Pandolfi, Pier Paolo (Cold Spring Harbor perspectives in medicine, 2018-04-02)
      Men who develop metastatic castration-resistant prostate cancer (mCRPC) will invariably succumb to their disease. Thus there remains a pressing need for preclinical testing of new drugs and drug combinations for late-stage ...
    • Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway. 

      Lee, Yu-Ru; Chen, Ming; Lee, Jonathan D; Zhang, Jinfang; Lin, Shu-Yu; Fu, Tian-Min; Chen, Hao; ... (27 authors) (Science (New York, N.Y.), 2019-05)
      Activation of tumor suppressors for the treatment of human cancer has been a long sought, yet elusive, strategy. PTEN is a critical tumor suppressive phosphatase that is active in its dimer configuration at the plasma membrane. ...
    • SPOP Promotes Nanog Destruction to Suppress Stem Cell Traits and Prostate Cancer Progression. 

      Zhang, Jinfang; Chen, Ming; Zhu, Yasheng; Dai, Xiangpeng; Dang, Fabin; Ren, Junming; Ren, Shancheng; ... (22 authors) (Developmental cell, 2019-02)
      Frequent SPOP mutation defines the molecular feature underlying one of seven sub-types of human prostate cancer (PrCa). However, it remains largely elusive how SPOP functions as a tumor suppressor in PrCa. Here, we report ...
    • Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis. 

      Lunardi, Andrea; Varmeh, Shohreh; Chen, Ming; Taulli, Riccardo; Guarnerio, Jlenia; Ala, Ugo; Seitzer, Nina; ... (20 authors) (Cancer discovery, 2015-05)
      UNLABELLED:The ETS family of transcription factors has been repeatedly implicated in tumorigenesis. In prostate cancer, ETS family members, such as ERG, ETV1, ETV4, and ETV5, are frequently overexpressed due to chromosomal ...
    • The APC/C E3 Ligase Complex Activator FZR1 Restricts BRAF Oncogenic Function. 

      Wan, Lixin; Chen, Ming; Cao, Juxiang; Dai, Xiangpeng; Yin, Qing; Zhang, Jinfang; Song, Su-Jung; ... (22 authors) (Cancer discovery, 2017-04)
      BRAF drives tumorigenesis by coordinating the activation of the RAS/RAF/MEK/ERK oncogenic signaling cascade. However, upstream pathways governing BRAF kinase activity and protein stability remain undefined. Here, we report ...
    • Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy. 

      Mugoni, Vera; Panella, Riccardo; Cheloni, Giulia; Chen, Ming; Pozdnyakova, Olga; Stroopinsky, Dina; Guarnerio, Jlenia; ... (22 authors) (Cell research, 2019-06)
      Although targeted therapies have proven effective and even curative in human leukaemia, resistance often ensues. IDH enzymes are mutated in ~20% of human AML, with targeted therapies under clinical evaluation. We ...
    • Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition. 

      González-Billalabeitia, Enrique; Seitzer, Nina; Song, Su Jung; Song, Min Sup; Patnaik, Akash; Liu, Xue-Song; Epping, Mirjam T; ... (20 authors) (Cancer discovery, 2014-08)
      Prostate cancer is the most prevalent cancer in males, and treatment options are limited for advanced forms of the disease. Loss of the PTEN and TP53 tumor suppressor genes is commonly observed in prostate cancer, whereas ...